GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » GF Value Rank

SNY (Sanofi) GF Value Rank : 9 (As of Oct. 31, 2024)


View and export this data going back to 2002. Start your Free Trial

What is Sanofi GF Value Rank?

Sanofi has the GF Value Rank of 9.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Competitive Comparison of Sanofi's GF Value Rank

For the Drug Manufacturers - General subindustry, Sanofi's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sanofi's GF Value Rank Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Sanofi's GF Value Rank falls into.



Sanofi GF Value Rank Related Terms

Thank you for viewing the detailed overview of Sanofi's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Sanofi Business Description

Address
46, avenue de la Great Army, Paris, FRA, 75017
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Sanofi Headlines

From GuruFocus

Q3 2022 Sanofi SA Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q4 2022 Sanofi SA Earnings Call Transcript

By GuruFocus Research 02-09-2024

Sanofi SA R&D Day Transcript

By GuruFocus Research 02-09-2024

Sanofi SA Vaccines Investor Event Transcript

By GuruFocus Research 02-09-2024

Q1 2023 Sanofi SA Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q2 2023 Sanofi SA Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q1 2024 Sanofi SA Earnings Call Transcript

By GuruFocus Research 04-26-2024